GlaxoSmithKline PLC is exploring a potential initial public offering of its HIV-focused subsidiary ViiV Healthcare , CEO Andrew Witty announced during the company’s Oct. 22 earnings call. Such a move would allow shareholders to better appreciate ViiV’s value and take advantage of a high-growth phase at the business fueled by the launch of Tivicay (dolutegravir).
The company is considering the sale of a minority stake in the business, Witty said. The subsidiary was established in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?